Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: China has been investigating 17 deaths following inoculation with a hepatitis B vaccine, made by Shenzhen-based BioKangtai, from December 13 and 31. The news alarmed many Chinese Internet users, who called on the government to make more information public. Many Chinese people are suspicious that the government tries to cover up bad news about health problems, despite assurances of transparency. In 2003, the government initially tried to cover-up the outbreak of the SARS virus. Nine of the cases have nothing to do with the vaccines, state news agency Xinhua cited the director of the disease control bureau of the National Health and Family Planning Commission, Yu Jingjin, as saying at a press conference. A preliminary analysis of the eight other cases have also found no link between the deaths and the vaccines, but the cause of the deaths will be confirmed only after autopsies, Yu said. Li Guoqing of the China Food and Drug Administration said at a press conference that no problems had been found with BioKangtai vaccines in production practices or product quality, according to Xinhua. BioKangtai said in a statement in December that it rigorously followed safety rules but that they were testing the batches suspected of causing the deaths. China has been beset by a series of product safety scandals over the past few years. At least six children died in 2008 after drinking milk contaminated by the industrial chemical melamine, and there have also been reports of children dying or becoming seriously ill from faulty encephalitis, hepatitis B and rabies vaccines.

Output: China says child deaths not linked to hepatitis vaccine.


Input: Consider Input: In a report released Wednesday, the experts said annual cases of Legionnaires’ jumped more than fivefold from 2000 to 2017, and that as many as 70,000 Americans get the disease every year. Legionnaires’ is caused by bacteria that can thrive in buildings with large water systems. About 20 outbreaks are reported each year, including recent ones at an Atlanta hotel and a hospital near Chicago. But there is no single set of widely accepted guidelines for preventing infections. The National Academies of Sciences, Engineering and Medicine report pushes for requirements like minimum temperature levels for hot-water heaters, and registration and monitoring of cooling towers.

Output: Experts call for steps to stem increases in Legionnaires’.


Input: Consider Input: We won’t require a discussion of costs in this story because the use of zoledronic acid for early stage breast cancer is still up in the air. However, since the drug is already being sold for other indications, the story would have been better if it had told readers something about the costs of using the drug for approved indications. The article accurately framed the only potential benefit documented by the AZURE study: that it might provide a recurrence and survival advantage among a subgroup of post-menopausal women… and that this results is something to be studied further. The article accurately reported on the incidence of a serious side effect among the women taking zoledronic acid. The article accurately characterized the main conclusions of the study and the results of a secondary subgroup analysis. It also told readers that an earlier trial reached a different conclusion and that other studies are underway, thus helping make clear that these results are just part of a larger picture. The story emphasized—through the quote of an independent expert—that the subgroup analysis indicating older women with early stage breast cancer might get some benefit should lead to further research rather than changing standard practice now. There was no hint of disease-mongering in this article. The article quoted an independent source. It also addressed conflicts-of-interest among the researchers. The story did point out that the women in this trial did receive standard therapy (and it did so more clearly than the other story we reviewed), though it did not specifically say what that treatment entails. We will give the story a satisfactory rating since it is not clear that there is a proven alternative that would provide the type of recurrence and survival benefits seen in a previous study of zoledronic acid for early stage breast cancer. The article did not make it clear that the FDA has not yet approved zoledronic acid as adjunctive treatment for women with early breast cancer. The article made it clear that zoledronic acid is already in use for other applications. The article did not appear to be overly reliant on a news release.


Output: Bone Drug Zometa Flops Overall as Breast Cancer Treatment